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Secreted Frizzled-related protein-1 is a negative regulator of
androgen receptor activity in prostate cancer
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Secreted Frizzled-related protein-1 (sFRP1) associates with Wnt proteins and its loss can lead to activation of Wnt/b-catenin
signalling. It is frequently downregulated in cancer, including prostate cancer, but its function in prostate cancer is unclear because it
can increase proliferation of prostate epithelial cells. We investigated the function of sFRP1 in androgen-dependent prostate cancer
and found that sFRP1 inhibited androgen receptor (AR) transcriptional activity. In addition, sFRP1 inhibited the proliferation of
androgen-dependent LNCaP cells but not of an androgen-independent subline LNCaP-r, suggesting a role in androgen-dependent
growth. The inhibition of AR by sFRP1 was unaffected by co-expression of Wnt3a, stabilised b-catenin or b-catenin shRNA,
suggesting it does not involve Wnt/b-catenin signalling. Wnt5a also inhibited AR and expression of Wnt5a and sFRP1 together did
not further inhibit AR, suggesting that Wnt5a and sFRP1 activate the same signal(s) to inhibit AR. However, sFRP1 inhibition of AR
was unaffected by inhibitors of kinases involved in Wnt/Ca2þ and Wnt/planar cell polarity non-canonical Wnt signalling. Interestingly,
the cysteine-rich domain of sFRP1 interacted with Frizzled receptors expressed in prostate cancer cells, suggesting that sFRP1/Frizzled
complexes activate a signal that leads to repression of AR. Taken together, these observations highlight the function of b-catenin-
independent Wnt signalling in the control of AR activity and provide one explanation for sFRP1 downregulation in prostate cancer.
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Wnt signalling is important in a wide variety of biological
processes and is frequently misregulated in cancer. Wnt ligands
bind to Frizzled and low-density lipoprotein receptor-related
protein 5/6 receptors, thereby activating the Wnt/b-catenin
pathway, also known as the canonical pathway, and the non-
canonical planar-cell polarity (PCP) (Boutros et al, 1998) and
protein kinase C (PKC)/Ca2þ pathways (Slusarski et al, 1997). In
the Wnt/b-catenin pathway, stimulation by Wnt ligand leads to
b-catenin accumulation in the cytoplasm and translocation to the
nucleus, where it associates with T-cell receptor/lymphoid
enhancer factor-1 (TCF/LEF-1) family transcription factors (Beh-
rens et al, 1996; Molenaar et al, 1996) and activates target genes
such as c-Myc (He et al, 1998).
Cytoplasmic and/or nuclear b-catenin, which is often used as an
indicator of activation of the Wnt/b-catenin pathway, is observed
in up to 71% of advanced prostate tumour specimens (Chesire
et al, 2002; de la Taille et al, 2003; Yardy et al, 2008). However,
unlike colon cancer, where either inactivating mutations in APC or
activating mutations in b-catenin are observed in most cases,
mutations in intracellular components of the Wnt signalling
pathway in prostate cancer are rare. For instance, 5% of prostate
tumours harboured activating mutations in b-catenin (Voeller
et al, 1998; Chesire et al, 2000), whereas changes in the coding
region of Axin1 were recently identified in 6% of advanced
prostate cancer (Yardy et al, 2008) and inactivating mutations in
APC have not been found in prostate cancer patients (Suzuki et al,
1994; Watanabe et al, 1996).
Wnt signalling is also regulated by Wnt antagonists such as
members of the secreted Frizzled-related protein (sFRP) family.
Secreted Frizzled-related proteins are glycoproteins that possess
two characteristic domains, the cysteine-rich domain (CRD) in the
N terminus and the Netrin-like (NTR) domain in the C terminus
(Hoang et al, 1996; Finch et al, 1997; Leyns et al, 1997). The CRDs
of sFRPs share homology with Frizzled CRDs, and it is thought that
the sFRP1 CRD is essential in antagonising Wnt signals by directly
binding to Wnts, thereby preventing Wnt interaction with
Frizzleds (Lin et al, 1997; Bafico et al, 1999; Dann et al, 2001;
Bhat et al, 2007). Although the NTR domain of sFRP1 does not
associate with Wnts, it is required for maximal Wnt inhibitory
activity (Bhat et al, 2007). Secreted Frizzled-related proteins are
involved in wide-ranging biological phenomena. The sFRP1 gene
is inactivated in many human cancers either as a result of
chromosomal deletions (Stoehr et al, 2004; Huang et al, 2007) or
promoter hypermethylation (Suzuki et al, 2002; Takada et al, 2004;
Lodygin et al, 2005; Lo et al, 2006; Shih et al, 2006; Veeck et al,
2006; Dahl et al, 2007; Huang et al, 2007; Nojima et al, 2007), and
loss of sFRP1 expression contributes to a poor prognosis
(Klopocki et al, 2004; Veeck et al, 2006).
The androgen receptor (AR) is a member of the nuclear receptor
superfamily, and is a key regulator of prostate cancer cell
proliferation and survival (Dehm and Tindall, 2007). The
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transcriptional activity of AR is regulated by interaction with
various cofactors (reviewed in Chesire and Isaacs, 2003 and
Cronauer et al, 2003), which include b-catenin (Truica et al, 2000;
Chesire et al, 2002; Mulholland et al, 2002; Yang et al, 2002).
Because both AR transcriptional activity and the cytoplasmic and/
or nuclear levels of b-catenin (Chesire et al, 2002; de la Taille et al,
2003) are elevated in prostate cancer, crosstalk between AR and
Wnt/b-catenin signalling pathways may contribute to prostate
cancer progression.
We have investigated how the expression level of sFRP family
members in prostate cancer cells affects AR signalling. We
hypothesised that loss of sFRP leads to activation of canonical
Wnt signalling and, as a result, increased AR transcriptional
activity. Our results indicate that sFRP1 represses AR, but that the
mechanism of repression is independent of Wnt/b-catenin
signalling.
MATERIALS AND METHODS
Cells and reagents
Cell lines were from the American Type Culture Collection
(Rockville, MD, USA), except for LNCaP-r cells that were obtained
from El-Nasir Lalani (Imperial College London). Cells were grown
as previously described (Mazor et al, 2004; Zhu et al, 2004; Kawano
et al, 2006). In some experiments normal growth media were
replaced with phenol red-free media (Invitrogen, Paisley, UK)
containing charcoal-stripped serum (First Link UK, Birmingham,
UK) and DHT (Sigma, St Louis, MO, USA). Anti-Myc monoclonal
antibody (9E10) was purchased from Sigma. Recombinant sFRP1
was purchased from R&D Systems (Abingdon, UK).
Plasmids
Expression plasmids for Myc-tagged full-length human sFRP1,
sFRP1-DCRD and sFRP1-D1 were generous gifts from Jeffrey S
Rubin (NCI, Bethesda, MD, USA). Expression plasmids for HA-
tagged wild-type and S37A mutant form of b-catenin were from
Stephen Byers (Georgetown University, Washington, DC, USA).
16xSuperTOPFLASH was from Randall Moon (University of
Washington, Seattle, WA, USA). For expression plasmids encoding
extracellular domains of human Frizzled fused to human IgG1
heavy chain (pSMT2-Fz1-IgG, pSMT2-Fz3-IgG, pSMT2-Fz4-IgG
and pSMT2-Fz6-IgG), cDNA was obtained by PCR using human
Frizzled cDNAs (Origene Technologies, Rockville, MD, USA).
Detailed methods including sequences of primers are available
upon request. Other plasmids and reporters used have been
described previously (Mazor et al, 2004; Zhu et al, 2004; Kawano
et al, 2006).
Colony formation assays
LNCaP cells (3 105 cells per well) or LNCaP-r cells (2 105 cells
per well) were plated in six-well plates and transfected with 2 mg of
expression plasmids encoding sFRP1 derivatives or pcDNA3.1 as
a negative control using FuGENE HD (Roche Diagnostics,
Burgess Hill, UK). After 2 days (LNCaP), or on the following
day (LNCaP-r), all transfected cells (LNCaP) cells or one-third of
transfected cells (LNCaP-r) were re-plated in 100 mm tissue culture
plates with 500mg ml1 G418 (Merck Chemicals, Nottingham, UK).
After 2 –3 weeks, colonies were visualised by crystal violet staining.
Colonies more than 2 mm in diameter were counted and the results
were plotted on graphs.
Transcription assays
All cells were transfected in triplicate in 24-well plates unless
otherwise stated, and each well of the 24-well plate was transfected
with 40 ng pDM-bGal as an internal control, 200 ng firefly
luciferase gene driven by various promoter sequences and the
expression plasmids as indicated. The total amount of DNA was
brought to 400 ng using empty pcDNA3.1 (Invitrogen). To measure
AR transcriptional activity, cells were incubated in hormone-
depleted medium before transfection, DHT or vehicle was added
24 h after transfection and cells were grown for a further 24 h.
Recombinant sFRP1 or kinase inhibitors were added to cells 24 h
after transfection of reporters. Transfected cells were incubated
with sFRP1 or kinase inhibitors for 25 h in hormone-depleted
medium and for an additional 24 h in the presence of DHT.
Measurement, normalisation and calculation of luciferase activity
were carried out as previously described (Mazor et al, 2004).
Generation of LNCaP/TR-bi cells
LNCaP cells expressing the Tet repressor (LNCaP/TR2) (Kawano
et al, 2006) were transfected with pTER-b-catenin (van de
Wetering et al, 2003) and selected for resistance to both 6 mg ml1
blasticidin and 300mg ml1 Zeocint (Invitrogen). Positive clones
were identified by western blotting for b-catenin.
RT–PCR
RT–PCR was performed essentially as described previously (Zhu
et al, 2004), but with modified PCR parameters (2 min at 941C, 30 s
at 941C, 30 s at 551C and 30 s at 721C for 35 cycles). Primers for
human Frizzleds were designed as reported by Sala et al (2000)
except Frizzled-8 (forward, 50-AAGACAGGCCAGATCGCTAA-30;
reverse, 50-GCCATGCCGAAGAAGTAGAC-30) and GAPDH (for-
ward, 50-TGTTGCCATCAATGACCCCTT-30; reverse, 50-CTCCACG
ACGTACTCAGCG-30).
IP and western analyses
293 cells (2 105 cells per well) were plated in six-well plates and
transfected with 50 ng sFRP1 derivatives and 950 ng Frizzled-IgG
using FuGENE HD. Cells were harvested 48 h following transfec-
tion and extracted using lysis buffer (0.5% Triton X-100, 10 mM
HEPES (pH 7.4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA),
supplemented with Complete, EDTA-free protease inhibitor cock-
tail tablets (Roche Diagnostics). Cell extracts were clarified by
centrifugation for 15 min at 16 000 g at 41C and processed for
protein A/G precipitation on a rotating wheel in a cold room for
1 h. After five washes in lysis buffer, the beads were re-suspended
in SDS sample buffer. For western blotting, extracts and IPs were
separated by SDS–PAGE, transferred to nitrocellulose membranes
and incubated in 5% Fraction V BSA in TBS-T (20 mM Tris (pH
7.5), 100 mM NaCl, 0.1% Tween 20) for 30 min. After probing with
antibodies, antigens were visualised using chemiluminescence
(ECL; GE Healthcare, Chalfont St Giles, UK).
RESULTS
Inhibition of AR transcriptional activity by sFRP1
We conducted RT– PCR analysis of sFRP family gene expression
using cell lines derived from normal prostate and prostate cancer
and confirmed previous reports (Lodygin et al, 2005) that sFRP1
expression is reduced in prostate cancer cells (data not shown). To
study whether sFRP1 could affect AR transcriptional activity, we
expressed sFRP1 in 22Rv1 cells, an AR-positive prostate cancer cell
line that does not express sFRP family members (data not shown),
together with the androgen-responsive reporter MMTV-luciferase
and a control reporter, and treated cells with the AR ligand
dihydrotestosterone (DHT). As expected, DHT increased AR
transcriptional activity (Figure 1A). Interestingly, transfection of
sFRP1 expression plasmid repressed AR activity in a dose-
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dependent manner. To confirm this result in a more physiological
context, we repeated these experiments using purified recombi-
nant sFRP1 and found that this also repressed AR transcriptional
activity (Figure 1B). In addition, RT–PCR analysis indicated that
recombinant sFRP1 reduced expression of the endogenous AR
target genes PSA and Kallikrein 2 (KLK2) (Figure 1C). These
results indicate that sFRP1 has an inhibitory effect on AR
transactivation in prostate cancer cells. To investigate which
domains of sFRP1 are required for repression of AR, we used
sFRP1 mutants lacking either the CRD (DCRD) or the C-terminal
half containing the NTR domain (D1) (Uren et al, 2000). D1 and
wild-type sFRP1 repressed AR to a similar extent, whereas DCRD
had a significantly weaker effect (Figure 2A). Similar results were
observed using LNCaP, another AR-expressing prostate cancer cell
line (Figure 2B). These results indicate that the CRD is important
for AR repression by sFRP1.
sFRP1 reduces proliferation of LNCaP cells but not of the
androgen-independent subline LNCaP-r
To determine the importance of the CRD in sFRP1 for androgen-
dependent prostate cancer cell proliferation, LNCaP cells and a
subline of LNCaP, LNCaP-r, which expresses AR but is hormone
resistant (Pousette et al, 1997), were transfected with empty vector,
sFRP1 or the sFRP1 deletion mutants and grown in medium
containing G418. Compared to empty vector, full-length sFRP1
and D1 significantly inhibited colony formation of LNCaP cells
(Figure 2D and F). DCRD also reduced colony formation in LNCaP
cells, but not to the same extent as full-length sFRP1 and D1
(Figure 2D and F). The growth inhibitory effects of the mutants
correlated with their effects on AR transcriptional activity in
LNCaP cells (Figure 2B). Interestingly, none of the sFRP1 constructs
inhibited colony formation of LNCaP-r cells (Figure 2E and G),
despite the fact that AR transcriptional activity was similarly
inhibited by sFRP1 in LNCaP and LNCaP-r cells (Figure 2B
and C). These results indicate that sFRP1 specifically represses
colony formation of androgen-dependent prostate cancer cells,
and that this repression is mediated principally through the
sFRP1 CRD.
Repression of AR by sFRP1 does not involve Wnt/b-catenin
signalling
Recently, Wnt3a was shown to enhance AR activity at low
concentrations of DHT (Verras et al, 2004). Because the sFRP1
CRD competes with Frizzled receptors for binding to Wnts
(Lin et al, 1997; Bafico et al, 1999), we hypothesised that sFRP1
represses AR by antagonising autocrine Wnt signals in prostate
cancer cells. If this is the case, then excess Wnt3a should rescue the
inhibitory effect of sFRP1 on AR. We tested this possibility by
conducting luciferase assays using a Wnt-responsive reporter
(Figure 3). 22Rv1 cells were found to have low but measurable
b-catenin/Tcf signalling activity (Figure 3A). Moreover, this
activity was repressed by sFRP1 and thus most likely resulted
from autocrine signals mediated by endogenous Wnts. The inhi-
bitory effects of sFRP1 on b-catenin/Tcf activity were prevented by
co-expression of Wnt3a (Figure 3A). We next examined the effect
of Wnt3a on sFRP1 repression of AR activity and found that
despite preventing sFRP1 repression of b-catenin/Tcf activity,
Wnt3a did not affect sFRP1 repression of AR activity (Figure 3B).
These results suggest that sFRP1 repression of AR is independent
of its ability to bind to endogenous Wnt ligands that activate
b-catenin/Tcf-dependent transcription.
Repression of AR by sFRP1 does not involve b-catenin
Secreted Frizzled-related protein-1 can also inhibit b-catenin/Tcf
activity in colon cancer cells with mutations in APC that stabilise
b-catenin (Suzuki et al, 2004). Moreover, exogenous high-level
expression of b-catenin increases AR transcriptional activity
independently of Tcf/LEF (Truica et al, 2000; Chesire et al, 2002;
Yang et al, 2002), suggesting that sFRP1 might repress b-catenin/
AR activity in a Wnt-independent manner. To investigate this, we
compared the effects of sFRP1 on b-catenin/Tcf and AR activities
in the presence of exogenous b-catenin (Figure 4). As expected,
expression of wild-type b-catenin increased b-catenin/Tcf activity,
and expression of a stable mutant form of b-catenin increased this
further (Figure 4A). AR activity was not significantly affected by
expression of wild-type b-catenin, but it was increased to a small
but significant extent by the stable mutant form of b-catenin
(Figure 4B). Interestingly, sFRP1 reduced the effects of wild-type
b-catenin and the stable mutant form of b-catenin on b-catenin/
Tcf activity to a similar extent (two-fold). It was clear that both
wild-type and the stable mutant forms of b-catenin still
significantly increased b-catenin/Tcf signalling (26-fold and 330-
fold higher than endogenous activity respectively) in sFRP1-
transfected cells (Figure 4A). Importantly, sFRP1 inhibited AR
activity to a similar extent independently of the expression of wild-
type and stabilised b-catenin (Figure 4B), suggesting that sFRP1
does not act through b-catenin to repress AR. To test this further,
we established LNCaP cell lines expressing b-catenin shRNA in a
doxycycline-inducible manner (LNCaP/TR-bi cells) (Figure 4C).
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Figure 1 sFRP1 inhibits AR signalling. (A) 22Rv1 cells were co-transfected with MMTV-luc, pDM-bGal and increasing amounts of sFRP1 expression
plasmid as indicated. At 24 h after transfection, cells were treated with 0.1 nM of the agonist DHT or an equivalent volume of vehicle (ethanol) for 24 h.
(B) 22Rv1 cells were co-transfected with MMTV-luc and pDM-bGal. At 24 h after transfection, cells were treated with or without 25 mg ml1 recombinant
sFRP1 for 5 h, and then further treated with 0.1 nM DHT or an equivalent volume of vehicle (ethanol) for 24 h. Data are average±standard deviation (s.d.) of
a representative experiment carried out in triplicate (*Po0.005; Student’s t-test). (C) RT–PCR for AR target genes in 22Rv1 cells treated with recombinant
sFRP1 and DHT.
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As we previously reported (Mazor et al, 2004), depletion of
endogenous b-catenin in 22Rv1 cells increased AR activity
(Figure 4D), suggesting that the function of endogenous b-catenin
differs from that of exogenously expressed b-catenin. Importantly,
depletion of b-catenin did not affect sFRP1 repression of AR
(Figure 4D), indicating that sFRP1 repression of AR does not require
endogenous b-catenin. To conclude, the inhibitory effects of sFRP1 on
AR do not appear to involve canonical Wnt signalling or b-catenin.
Repression of AR by sFRP1 does not involve kinases
implicated in non-canonical Wnt signalling
Non-canonical Wnt pathways, such as the PKC/Ca2þ and PCP
pathways, involve several key kinases, including PKC, calmodulin
kinase II (CaMKII), c-Jun N-terminal kinase (JNK) and ROCK,
which all have the potential to regulate AR transcriptional activity
(de Ruiter et al, 1995; Sato et al, 1997; Muller et al, 2000, 2002;
Jeong et al, 2004; Backs et al, 2006). We reasoned that if sFRP1
repression of AR involves any of these kinases, then inhibitors that
target these kinases would not further repress AR in the presence
of sFRP1. To test this possibility, 22Rv1 cells were transfected with
empty vector or sFRP1 and treated with a panel of kinase
inhibitors (Figure 5A). In the absence of sFRP1, the PKC inhibitor
GF109203X and the ROCK inhibitor H-1152 did not affect AR
transcriptional activity, whereas the CaMKII inhibitor KN-62
repressed AR activity and the JNK inhibitor SP600125 increased
AR activity (Figure 5B). Importantly, sFRP1 repressed AR
regardless of the presence of any of these kinase inhibitors, with
none of the kinase inhibitors significantly reducing the sFRP1 fold
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Figure 2 (A–C) sFRP1 represses AR transcriptional activity and androgen-dependent proliferation of prostate cancer cells principally through the CRD.
(A) 22Rv1 cells. (B) LNCaP cells. (C) LNCaP-r cells. All cells were transfected in triplicate in six-well plates, and each well of the six-well plate was
transfected with 0.2 mg pDM-bGal as an internal control, 1mg MMTV-luc and 0.4 mg expression plasmid of sFRP1 derivative. Empty pcDNA3.1 plasmid was
used as a negative control. The total amount of DNA was brought to 2 mg using empty pcDNA3.1. At 24 h after transfection, cells were treated with
indicated concentration of DHT or an equivalent volume of vehicle (ethanol) for 24 h. Secreted Frizzled-related protein-1 or its derivatives were expressed
at comparables level in all cell lines tested (see Supplementary Information 1A–C). (D–G) sFRP1 reduces colony formation of LNCaP cells but not of the
androgen-independent subline LNCaP-r. LNCaP cells (D and F) or LNCaP-r cells (E and G) were transfected with sFRP1 or its derivatives, and the number
of colonies was determined as described in ‘Experimental procedures’.
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repression of AR compared to empty vector. These results suggest
that serine/threonine kinases implicated in non-canonical Wnt
signalling are not required for sFRP1 repression of AR.
Interaction of sFRP1 with Frizzled receptors expressed in
prostate cancer cells
Recent reports indicate that sFRP1 can also directly interact with
Frizzled receptors to trigger intracellular signals (Bafico et al, 1999;
Rodriguez et al, 2005). Therefore, we hypothesised that sFRP1
represses AR by activating a Frizzled-mediated signal. To identify
candidate Frizzled receptors that could be involved, RT–PCR was
performed using specific primers targeting each Frizzled family
member in a panel of normal prostate and prostate cancer cell
lines. Frizzled-1, -2, -3, -4 and -6 were expressed in all prostate cell
lines examined (Figure 6A). Because Frizzled-2 expression was
relatively weak in the AR-expressing prostate cancer cell lines
(22Rv1 and LNCaP), Frizzled-1, -3, -4 and -6 were chosen for the
further analysis. To explore the possibility that sFRP1 interacts
with these Frizzleds, the extracellular domains of these family
members (containing the CRD) were fused to the Fc domain
of human IgG1 and expressed in HEK 293 cells together with
full-length or deletion mutants of sFRP1 (Figure 6B). Immuno-
precipitation (IP) analysis showed that all Frizzled –Fc fusion
proteins interacted with full-length sFRP1 and D1 but not with
DCRD (Figure 6B). These results indicate that the sFRP1 CRD is
required for interaction with Frizzled-1, -3, -4 and -6. Although
further studies will be required, these results raise the interesting
possibility that sFRP1 repression of AR is mediated by signals
acting directly through Frizzleds. Secreted Frizzled-related protein-
1 regulates axon growth of retinal ganglion cells through direct
binding to Frizzled and activation of a trimeric G-protein pathway
that can be blocked by pertussis toxin (PTX) (Rodriguez et al,
2005). We therefore tested the effect of repressing trimeric G-
protein signals on sFRP1 inhibition of AR by treating 22Rv1 cells
with PTX. As shown in Figure 6C, sFRP1 repression of AR was not
affected by PTX, suggesting that sFRP1 repression of AR does not
involve PTX-sensitive G-protein signals.
These results suggest that the sFRP1/Frizzled interaction might
repress AR through a novel signalling pathway. Although we have
ruled out canonical and several of the non-canonical Wnt signals
in the repression of AR by sFRP1, Wnt5a is thought to activate
additional, as yet uncharacterised, signals (Mikels and Nusse,
2006). Therefore, we examined the effect of Wnt5a on AR activity
in 22Rv1 cells. Wnt5a repressed AR, and expression of Wnt5a and
sFRP1 together did not lead to further inhibition of AR
(Figure 6D), suggesting that sFRP1 and Wnt5a activate the same
signalling pathway(s) to repress AR.
DISCUSSION
Secreted Frizzled-related protein-1 expression is downregulated in
many cancers including prostate cancer (Ugolini et al, 2001;
Suzuki et al, 2002; Caldwell et al, 2004; Klopocki et al, 2004; Stoehr
et al, 2004; Takada et al, 2004; Lodygin et al, 2005; Lo et al, 2006;
Shih et al, 2006, 2007; Veeck et al, 2006; Dahl et al, 2007; Huang
et al, 2007; Nojima et al, 2007). Because sFRP1 is a Wnt antagonist
and the Wnt/b-catenin/TCF axis is aberrantly activated in cancer,
it is plausible that downregulation of sFRP1 contributes to
abnormal activation of the b-catenin/TCF complex. This is indeed
the case in some tumours, where restoration of sFRP1 expression
inhibits both b-catenin/TCF activity and cancer cell growth
(Suzuki et al, 2004; Nojima et al, 2007; Shih et al, 2007). However,
although both downregulation of sFRP1 and accumulation of
cytoplasmic b-catenin are frequently observed in prostate cancer
(Chesire et al, 2002; de la Taille et al, 2003; Lodygin et al, 2005), b-
catenin/TCF activity is much lower than in cancers such as colon
cancer, in which b-catenin/TCF signalling is essential for tumour
cell growth (Lodygin et al, 2005; YK and RMK, unpublished
observations). Therefore, it is important to consider the possibility
that loss of sFRP1 affects signalling pathways other than those
mediated by b-catenin/TCF, and that these drive prostate cancer
cell proliferation. In this paper, we have shown that sFRP1
represses AR-dependent transcription both in androgen-depen-
dent LNCaP cells and in the androgen-independent derivative,
LNCaP-r. Importantly, sFRP1 inhibited colony formation of
LNCaP cells but not of LNCaP-r cells, thus linking the growth
inhibitory effects of sFRP1 to androgen-dependent proliferation of
prostate cancer cells.
Secreted Frizzled-related protein-1 also reduced the mRNA
expression levels of the androgen-regulated genes PSA and KLK2
in 22Rv1 cells. These findings are consistent with a recent report
by Joesting et al (2005) demonstrating that sFRP1 negatively
regulates expression of androgen-regulated proteins by prostate
luminal epithelial cells in vivo. Joesting et al also have shown
evidence that proliferation of prostate epithelial cells is reduced in
Sfrp1 null mice and increased in sFRP1 transgenic mice. These
observations might appear to contradict our results. However, the
function of AR in normal prostate epithelial cells in vivo is anti-
proliferative (Wu et al, 2007), whereas AR has proliferative
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Figure 3 Repression of AR by sFRP1 does not involve Wnt/b-catenin
signalling. 22Rv1 cells were transfected with luciferase reporter gene
(A, 16XSuperTOPFLASH; B, MMTV-luc), pDM-bGal, 80 ng of sFRP1
plasmid and 80 ng of Wnt3A plasmid as indicated. At 24 h after
transfection, cells were treated with 0.1 nM DHT or an equivalent volume
of vehicle (ethanol) for 24 h (*Po0.00002; Student’s t-test). Western
blotting of cell lysates shows comparable expression of sFRP1 (Supple-
mentary Information 2A). The levels of Wnt3A were too low to be
detected by western blotting in these experiments.
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function in prostate cancer. Thus, the mouse phenotypes may, at
least in part, reflect the function of sFRP1 in the regulation of AR
transcriptional activity in the normal prostate.
We have found that the sFRP1 mutant comprising the CRD but
not the NTR domain (D1) inhibited both AR activity and colony
formation to the same extent as wild-type sFRP1, whereas the
sFRP1 mutant comprising the NTR domain but not the CRD
(DCRD) had a weaker effect in both assays (Figure 2). These results
indicate that the CRD has an important function in the repression
of AR by sFRP1. It is intriguing that DCRD retains some inhibitory
activity. The NTR domain in this mutant has affinity for heparin,
and so it is possible that it sequesters heparan-sulphate
proteoglycans and inhibits serum growth factors such as FGF-2,
which has been shown to regulate androgen-dependent AR activity
and LNCaP cell growth (Kassen et al, 2000). However, in the
context of full-length sFRP1, it is clear that the CRD has the
predominant function in repressing AR.
Because sFRP1 is best known as a Wnt antagonist, it is plausible
that it represses AR by sequestering endogenous Wnt ligands
secreted by prostate cancer cells. Indeed, we have previously
reported that prostate cancer cell lines express several Wnt family
members (Zhu et al, 2004). Therefore, we tested whether Wnt3a,
which directly binds to sFRP1 and has been reported to potentiate
AR activity in LNCaP cells (Verras et al, 2004), could rescue sFRP1
inhibition of AR. In contrast to what was reported for LNCaP cells,
Wnt3a did not significantly increase AR activity in 22Rv1 cells
(Figure 3B), consistent with a previous report using this cell line
(Cronauer et al, 2005). Moreover, although co-expression of Wnt3a
rescued sFRP1 repression of b-catenin/Tcf activity in 22Rv1 cells
(Figure 3A), it had no effect on sFRP1 repression of AR activity
(Figure 3B). This suggests that repression of AR by sFRP1 does not
involve sequestration of endogenous canonical Wnt signals that
might be responsible for activating AR.
Similarly, co-expression of b-catenin enhanced b-catenin/Tcf
activity in 22Rv1 cells (Figure 4A), but had no effect on sFRP1
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Figure 4 Repression of AR by sFRP1 does not involve b-catenin. (A and B) 22Rv1 cells were transfected with luciferase reporter gene
(A, 16xSuperTOPFLASH; B, MMTV-luc), pDM-bGal, 80 ng of sFRP1 plasmid and 80 ng of wild-type (WT) or S37A mutant (SA) b-catenin plasmid as
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shows comparable expression of sFRP1 and b-catenin (Supplementary Information 2B). (C) Establishment of an LNCaP subline that expresses a
Dox-inducible b-catenin shRNA. Doxycycline (Dox, 1mg ml1) was added to LNCaP/TR-bi cells, and cytosolic extracts were analysed for the level of
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Figure 5 Repression of AR does not involve kinases implicated in non-
canonical Wnt signalling. 22Rv1 cells were co-transfected with 80 ng of
sFRP1 plasmid, MMTV-luc and pDM-bGal. At 24 h after transfection, cells
were treated with GF109203X (2.5mM), KN-62 (10 mM), SP600125
(10 mM), H-1152 (1mM) or an equivalent volume of vehicle for 5 h, and
then further treated with 0.1 nM DHT for 24 h.
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repression of AR activity (Figure 4B). Despite having relatively low
b-catenin/Tcf activity, prostate cancer cell lines contain significant
amounts of cytoplasmic b-catenin. Therefore, it was important to
determine whether sFRP1 repression of AR required endogenous
b-catenin. Our experiments using shRNA to deplete b-catenin
clearly showed that endogenous b-catenin is not required for
sFRP1 repression of AR (Figure 4C and D).
Secreted Frizzled-related protein-1 can also interact with Wnt
proteins that are involved in so-called Wnt non-canonical
signalling pathways, including the Ca2þ /PKC (Slusarski et al,
1997) and PCP pathways (Boutros et al, 1998). Activation of these
pathways is thought to involve PKC, CaMKII (Slusarski et al,
1997), JNK (Boutros et al, 1998) and ROCK (Marlow et al, 2002).
Several of these kinases can affect AR signalling: CaMKII
phosphorylates and inactivates HDAC4 (Backs et al, 2006), which
represses AR (Jeong et al, 2004), ROCK activates FHL2, a co-
activator for AR (Muller et al, 2000, 2002) and JNK activates AP-1,
which can repress AR (Sato et al, 1997). Consistent with some of
these reports, both KN-62 (a CaMKII inhibitor) and SP600125 (a
JNK inhibitor) affected AR activity in 22Rv1 cells (Figure 3B).
However, none of the kinase inhibitors tested was able to mimic or
rescue sFRP1 inhibition of AR. Activation of CaMKII and JNK was
also monitored in 22Rv1 cells expressing sFRP1 or treated with
recombinant sFRP1 by western analysis using phospho-specific
antibodies. However, neither kinase was activated by sFRP1 in
22Rv1 cells (YK and RMK, unpublished observations), suggesting
that sFRP1 repression of AR is not mediated by the kinases
implicated in the Ca2þ /PKC or PCP pathways.
Recent reports indicate that sFRP proteins can signal indepen-
dently of Wnts (Bovolenta et al, 2008). Rodriguez et al (2005), for
example, showed that sFRP1-induced axonal outgrowth growth is
mediated by a direct interaction between sFRP1 and Frizzled-2.
The effects of sFRP1 were mediated by the CRD and involved
activation of heterotrimeric G proteins (Rodriguez et al, 2005).
Although we found that the CRD of sFRP1 is able to interact with
each of four frizzled family members that are highly expressed in
AR-expressing prostate cancer cell lines, sFRP1 repression of AR
was not rescued by PTX treatment, indicating that G proteins are
not involved in this phenomenon.
It is intriguing that Wnt5a and sFRP1 inhibited AR to a similar
extent. Moreover, co-transfection of sFRP1 and Wnt5a did not
produce an additive effect on repression of AR. Wnt5a was recently
reported to activate novel signalling pathways (Yamamoto et al,
2007; Fukuda et al, 2008). There are conflicting data on whether
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Figure 6 sFRP1 associates with Frizzled receptors expressed in prostate cancer cells. (A) RT–PCR analysis of Frizzled expression in normal prostate and
prostate cancer cell lines. G, GAPDH. (B) 293 cells were co-transfected with sFRP1 derivatives and Frizzled-IgG, then cell lysates were analysed by
immunoprecipitation with protein A/G agarose and western blotting with anti-myc directly (top). To confirm immunoprecipitation of Frizzled-IgG, the
immunoprecipitated sample was analysed by western blotting with anti-human IgG antibody (middle). To confirm expression of sFRP1 derivatives in cells,
total lysate was analysed by western blotting with anti-myc antibody (bottom). W, sFRP1 wild type; C, sFRP1-DCRD; 1, sFRP1-D1. (C) 22Rv1 cells were co-
transfected with MMTV-luc and pDM-bGal. At 24 h after transfection, cells were treated with the indicated concentration of PTX or an equivalent volume of
vehicle for 5 h, and then further treated with 0.1 nM DHT or an equivalent volume of vehicle (ethanol) for 24 h. (D) 22Rv1 cells were co-transfected with
80 ng of sFRP1 plasmid, 80 ng of Wnt5a plasmid, MMTV-luc and pDM-bGal. At 24 h after transfection, cells were treated with 0.1 nM DHT or an equivalent
volume of vehicle (ethanol) for 24 h. Western blotting of cell extracts shows comparable expression of sFRP1 and Wnt5a (Supplementary Information 2C).
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sFRP1 and Wnt5a directly interact (Dennis et al, 1999; Wawrzak
et al, 2007), but it is plausible that sFRP1 and Wnt5a activate a
common downstream pathway(s) that leads to AR inhibition.
Future work will address whether signals downstream of Frizzleds
affect AR function. One possibility is the involvement of Ror1/2
(Hikasa et al, 2002; Oishi et al, 2003; Fukuda et al, 2008), receptor
tyrosine kinases that contain a CRD that binds to Wnt5a (Oishi
et al, 2003) and to Frizzleds (Li et al, 2008). The signals
downstream of Ror1/2 have not been characterised, but it would
be interesting to investigate whether there is a molecular link
between Ror1/2 and AR. Alternatively, sFRP1 may inhibit AR
through a mechanism that involves the receptor activator of
nuclear factor-kB ligand (RANKL). Secreted Frizzled-related
protein-1 was reported to inhibit RANKL-dependent osteoclast
formation (Hausler et al, 2004) and RANKL is found in prostate
cancer cells, where it is thought to mediate the effects of prostate
tumour cells on osteoclastogenesis in vivo (Zhang et al, 2001).
A more recent report indicates that many cancer cells (including
the prostate cancer line LNCaP) express RANK and respond to
RANKL (Jones et al, 2006).
To summarise, we have shown that sFRP1 represses AR
transcriptional activity and, as a result, inhibits proliferation of
androgen-dependent prostate cancer cells and that the CRD is
mainly responsible for both of these effects. We have addressed the
possible mechanisms of action of sFRP1 and demonstrated that
repression of AR by sFRP1 does not involve signals mediated by
canonical Wnts, b-catenin or by kinases implicated in Wnt/Ca2þ
and Wnt/PCP signalling. Taken together with our demonstration
that sFRP1 can associate with Frizzleds expressed in prostate
cancer cells, we propose that sFRP1/Frizzled complexes activate a
signal that leads to repression of AR and that inactivation of sFRP1
leads to uncontrolled AR activation, which may be a crucial step in
prostate cancer progression.
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